Abstract
Since its first suggestion as possible option for liver radioembolization treatment, the therapeutic isotope holmium-166 ((166)Ho) caught the experts' attention due to its imaging possibilities. Being not only a beta, but also a gamma emitter and a lanthanide, (166)Ho can be imaged using single-photon emission computed tomography and magnetic resonance imaging, respectively. Another advantage of (166)Ho is the possibility to perform the scout and treatment procedure with the same particle. This prospect paves the way to an individualized treatment procedure, gaining more control over dosimetry-based patient selection and treatment planning. In this review, an overview on (166)Ho liver radioembolization will be presented. The current clinical workflow, together with the most relevant clinical findings and the future prospective will be provided.